LumiThera_FDA
November 5, 2024

FDA Approves Lumithera’s Photobiomodulation Device for Dry AMD

Lumithera’s Valeda becomes the first FDA-approved treatment for vision loss caused by dry AMD Dry AMD sufferers in the United…

latest posts
FDA Rejects Regeneron’s Bid to Extend EYLEA HD Dosing Beyond 16 Weeks
April 22, 2025

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

WhatsApp Image 2024 11 25 at 10.06.27 am
December 2, 2024

SUBTHRESHOLD LASER TREATMENT—To Titrate or Not to Titrate?

Website thumbnail 2
November 12, 2024

Neurotech’s NT-501 BLA for MacTel Treatment Delayed for Additional FDA Review

LumiThera_FDA
November 5, 2024

FDA Approves Lumithera’s Photobiomodulation Device for Dry AMD

CAKE 24 (2)
October 21, 2024

AAO 2024 Retina Ophthalmic Technology Assessments: Tips for Your Practice

Untitled 1
August 20, 2024

Atsena Therapeutics Receives FDA RPD Designation for X-Linked Retinoschisis Gene Therapy Candidate

shutterstock_1317546590
July 17, 2024

Cutting-Edge Ocular Therapies

Montage_photo_Filloy_def_17072023
December 4, 2023

SubLiminal Laser Therapy for CSCR: A New Front-line Treatment

Discover our fascinating content at issuu

explore